CIK 0002044950
Bambusa Therapeutics, Inc.
Sign in to watch- Ticker
- BBTX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- other
- EIN
- 992083913
- Phone
- (617) 848-6188
- Business address
- 22 BOSTON WHARF ROAD, FLOOR 7, BOSTON, MA
- Open-market buys, last 90 days
- $58,639,957
- in 3 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$58,639,957. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-02 | RA CAPITAL MANAGEMENT, L.P. Director | Conversion | +3,144,858 | 3,598,678 | ||
| 2026-11-02 | RA CAPITAL MANAGEMENT, L.P. Director | Conversion | +1,331,080 | 1,331,080 | ||
| 2026-11-02 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | +2,335,109 | $16.00 | $37.4M | 5,933,787 |
| 2026-11-02 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | +164,891 | $16.00 | $2.6M | 1,495,971 |
| 2026-11-02 | RA CAPITAL MANAGEMENT, L.P. Director | Conversion · Series A-1 Preferred Stock | −2,844,910 | 0 | ||
| 2026-11-02 | RA CAPITAL MANAGEMENT, L.P. Director | Conversion · Series A-1 Preferred Stock | −1,278,148 | 0 | ||
| 2026-11-02 | RA CAPITAL MANAGEMENT, L.P. Director | Conversion · Series A-2 Preferred Stock | −299,948 | 0 | ||
| 2026-11-02 | RA CAPITAL MANAGEMENT, L.P. Director | Conversion · Series A-2 Preferred Stock | −52,932 | 0 | ||
| 2026-11-02 | Salvia Investment GmbH 10% owner | Conversion | +4,769,701 | 8,889,301 | ||
| 2026-11-02 | Salvia Investment GmbH 10% owner | Purchase | +375,000 | $16.00 | $6.0M | 9,264,301 |
| 2026-11-02 | Salvia Investment GmbH 10% owner | Conversion · Series Seed Plus Preferred Stock | −3,135,066 | 0 | ||
| 2026-11-02 | Salvia Investment GmbH 10% owner | Conversion · Series A-1 Preferred Stock | −1,473,775 | 0 | ||
| 2026-11-02 | Salvia Investment GmbH 10% owner | Conversion · Series A-2 Preferred Stock | −160,860 | 0 | ||
| 2026-11-02 | Xu Shanshan See remarks | Conversion | +16,358 | 840,277 | ||
| 2026-11-02 | Xu Shanshan See remarks | Conversion | +147,238 | 7,562,518 | ||
| 2026-11-02 | Xu Shanshan See remarks | Conversion · Series Seed Plus Preferred Stock | −4,155 | 0 | ||
| 2026-11-02 | Xu Shanshan See remarks | Conversion · Series Seed Preferred Stock | −10,450 | 0 | ||
| 2026-11-02 | Xu Shanshan See remarks | Conversion · Series A-1 Preferred Stock | −1,753 | 0 | ||
| 2026-11-02 | Xu Shanshan See remarks | Conversion · Series Seed Plus Preferred Stock | −37,399 | 0 | ||
| 2026-11-02 | Xu Shanshan See remarks | Conversion · Series Seed Preferred Stock | −94,050 | 0 |
Page 1 of 2 · 30 trades